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Introduction and aim of the study: Transurethral resection of prostate (TURP) still 
represents the gold standard in the surgical treatment of symptomatic benign prostatic 
hyperplasia (BPH).  The most frequent complication is represented by intra- and 
perioperative bleeding. Preoperative use of 5-alpha-reductase inhibitors (finasteride or 
dutasteride) to reduce surgical bleeding is still a topic of debate in literature. Previous 
studies provided favorable data on blood loss reduction by preoperative administration of 
finasteride or dutasteride. The aim of this study was to evaluate whether pretreatment with 
dutasteride for six weeks before surgery can reduce surgical blood loss. 
Materials and methods: A total of 142 patients with BPH-who were to undergo TURP-
were enrolled and randomized into two groups. The dutasteride group comprising of 71 
patients, was treated with dutasteride(0.5 mg/day) for 6 weeks before surgery and the 
control group, comprising of other 71 patients, did not receive dutasteride. Blood loss was 
evaluated in terms of a reduction in the serum hemoglobin level (ΔHb and ΔHCT), and 
was estimated by measuring the Hb and hematocrit levels before and 24 hours after 
surgery.  
Results: None of the patients treated with dutasteride reported any side effects. There 
was no statistically significant difference between the two groups with regard to age, 
prostate volume, resected prostate weight, PSA, and operation time.A significantly lower 
mean blood loss was observed in the dutasteride group compared to the control group 
(ΔHb= -1.29±0.81 vs. -1.83±1.25, respectively, p<0.0027; ΔHCT= -5.67±2.58 vs. -
6.50±2.40, respectively, p<0.0491).  
Conclusions: None of the previous studies had used dutasteride for 6 weeks before 
surgery. The results of the present study showed that treatment with dutasteride for 
6weeks before TURP reduces surgical bleeding. Although, in most cases the drop in 
HCT/Hgb (while statistically significant) was not clinically significant, but it is important 
considering that we have enrolled a large number of patients (i.e., 71) in each group.  
 
